Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 53

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 53
---
 MIRA in connection with the Merger. SKNY had previously never been subject to a third-party valuation. Moore was selected due to its global presence, and in particular, its presence in and familiarity with the markets and professional customs in Europe and the United States. Further, MIRA selected Moore because of its strong reputation in the field and recommendations from other similar companies. Moore’s staff have several years of experience in economic and financial consulting to some of the most prestigious businesses, acting in management positions in leading consulting firms. MIRA had no material relationship or affiliation with Moore over the past two years.

The fairness opinion and valuation reports were not prepared for the benefit of MIRA’s shareholders and accordingly, MIRA’s shareholders are not entitled to rely on the fairness opinion and valuation reports. Additionally, the fairness opinion does not opine on the fairness of the Exchange Ratio to MIRA or MIRA’s shareholders.

On April 30, 2025, Moore rendered its fairness opinion and valuation reports to the MIRA Board, the MIRA Chief Executive Officer and the MIRA Chief Scientific Officer, subsequently confirmed by delivery to MIRA of a written fairness opinion and valuation reports dated April 2025.

At the meeting dated April 30, 2025, Moore rendered its oral discussion of its determination of valuations of MIRA and SKNY to the Chairman of the MIRA Board, the MIRA Chief Executive Officer and the MIRA Chief Scientific Advisor, based upon and subject to the factors and assumptions set forth in its report. Moore confirmed its oral opinion by delivering its written opinion to MIRA, dated April 22, 2025. On May 22, 2025, Moore provided MIRA with a revised fairness addressing additional details related to SKNY’s business.

The full text of the fairness opinion and valuation report of Moore dated May 22, 2025, which set forth, among other things, the assumptions made, matters considered and limits on the review undertaken, is attached as Annex D to this proxy statement and is incorporated herein by reference. The summary of the opinion of Moore set forth in this proxy statement is qualified in its entirety by reference to the full text of such fairness opinion and valuation reports. MIRA’s shareholders are urged to read the fairness opinion and valuation reports in their entirety. Moore’s fairness opinion and valuation report was addressed to MIRA in connection with and for the purposes of its valuation of MIRA and SKNY in the proposed Merger, and did not address any other aspect of the Merger. Moore